Favourable outcome of a pregnancy with a maraviroc-containing regimen

Journal of AIDS and Clinical Research

Volumn 2, Issue 6, 2011, Pages

  Jeantils, Vincent ^a   Tigazin, Ahmed ^a   Lachassine, Eric ^a   Rodrigues, Anabela ^a   Bentata, Michelle ^b   Peytavin, Gilles ^c  

^a HÔPITAL JEAN VERDIER   (France)

^b AVICENNE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral agents; HIV infection; Maraviroc; Multiresistant virus; Pregnancy

Indexed keywords

EID: 84879803670     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000134     Document Type: Article

References (9)

1. French Hospital Database on HIV (FHDH)-Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) CO4.
2. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
3. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, et al. (2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22: 289-299.
4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Eng J Med 359: 1429-1441.
5. Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M (2010) Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother 54: 4059-4063.
6. Celsentri 150mg and 300mg film-coated tablets (2008) Summary of Product Characteristics.
7. Jones AE, Talameh JA, Patterson KB, Rezk NL, Prince HA, et al. (2009) First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam.
8. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, et al. (2009) Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIVnegative women. J Acquir Immune Defic Syndr 51: 546-553.
9. th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA.